CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, Journal Year: 2023, Volume and Issue: 9(11), P. e21776 - e21776

Published: Nov. 1, 2023

For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these help to improve condition, most tumors still have a poor prognosis. In recent immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell (CAR-T) uses patient's own T cells express chimeric receptors. (CAR) recognizes tumor-associated antigens kills cells. CAR-T achieved good results hematological tumors. 2017, FDA approved first for B-cell acute lymphoblastic leukemia (ALL). October same year, treat lymphoma. order enhance therapeutic effect, become research focus years. The structure CAR, targets treatment, adverse reactions improvement measures during process summarized. This review is an attempt highlight possibly forgotten findings advances cell

Language: Английский

---

Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC

Trends in cancer, Journal Year: 2024, Volume and Issue: 10(5), P. 457 - 474

Published: Feb. 15, 2024

Neutrophils represent the most abundant myeloid cell subtype in non-small-cell lung cancer (NSCLC) tumor microenvironment (TME). By anti- or protumor polarization, they impact multiple aspects of biology and affect sensitivity to conventional therapies immunotherapies. Single-cell RNA sequencing (scRNA-seq) analyses have unraveled an extensive neutrophil heterogeneity, helping our understanding their pleiotropic role. In this review we summarize recent data models on tumor-associated (TAN) biology, focusing diversity that evolves response tumor-intrinsic cues. We categorize available transcriptomic profiles from different entities into a defined set subclusters with distinct phenotypic properties, step beyond traditional binary N1/2 classification. Finally, discuss potential ways exploit these states setting anticancer therapy.

Language: Английский

---

Targeting neutrophils: Mechanism and advances in cancer therapy

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(3)

Published: March 1, 2024

Abstract Background Cancer is a thorny problem which cannot be conquered by mankind at present and recent researchers have put their focus on tumor microenviroment. Neutrophils, the prominent leukocytes in peripheral blood that accumulate tumours, serves as frontline cells response to tumour progression owing rapid development of micro biotechnology. Hence, targeted therapy with these neutrophils has made targeting treatment promising field cancer therapy. Main body We broadly summarise some studies phenotypes functions tumour‐associated well unique web‐like products play role progression—neutrophil extracellular traps—and interactions between microenvironment. Moreover, several therapeutic progress provided potential strategies for cancer. Conclusion This review aims offer holistic perspective interventions further inspire more researches therapies.

Language: Английский

---

Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: June 2, 2024

Radiotherapy combined with immune checkpoint blockade holds great promise for synergistic antitumor efficacy. Targeted radionuclide therapy delivers radiation directly to tumor sites. LNC1004 is a fibroblast activation protein (FAP)-targeting radiopharmaceutical, conjugated the albumin binder Evans Blue, which has demonstrated enhanced uptake and retention in previous preclinical clinical studies. Herein, we demonstrate that

Language: Английский

---

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 24, 2024

Language: Английский

---